Efficacy and Safety of BGG492 in the Treatment of Migraine

Completed · Phase 2 · Has a placebo group

Conditions studied: Migraine

In brief

This study will assess the efficacy and safety of BGG492 used to treat migraine pain.

Key facts

Study ID

NCT00892203

Run by

Novartis

People needed

75

Starts

2009-04-01

Expected to finish

2010-08-01

Last updated by the study team

2020-12-17

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of moderate to severe migraine for at least 1 year
• At least 1 migraine episode, but not more 15 migraine days per month
• Past use of triptans
• Migraine onset before 50 years of age

You may not qualify if…

• Diagnosis of basilar, ophthalmoplegic or hemiplegic migraine.
• More than 6 non-migraine headaches per month
• Patients receiving migraine prophylaxis treatment
• Patients receiving regular treatment with psychoactive drugs
• Smokers
• Patients with a very high or low body weight Other protocol-defined inclusion/exclusion criteria may apply

Where it is running

• California Clinical Trials, 1560 Chevy Chase Drive, Suite 140 — Glendale, California, United States
• California Clinical Trials, 15625 Lakewood Boulevard — Paramount, California, United States
• Novartis Investigative Site — Berlin, Germany
• Novartis Investigative Site — Essen, Germany
• Novartis Investigative Site — Göttingen, Germany
• Novartis Investigator Site — Hamburg, Germany
• Novartis Investigative Site — Kiel, Germany
• Novartis Investigative Site — Königstein, Germany
• Novartis Investigative Site — Munich, Germany
• Novartis Investigator Site — Munich, Germany
• Novartis Investigative Site — Münster, Germany
• Novartis Investigative Site — Würzburg, Germany
• Novartis Investigative Site — Barcelona, Spain

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.